[1]梁 芸,万玲玲,李玉雪,等.Titin抗体检测在重症肌无力并发胸腺瘤诊断中的价值[J].现代检验医学杂志,2016,31(04):38-40.[doi:10.3969/j.issn.16717-414.2016.04.009]
　LIANG Yun,WAN Ling-ling,LI Yu-xue,et al.Clinical Significance of Titin Antibody Detection in the Diagnosis of Myasthenia Gravis Combined Thymoma[J].Journal of Modern Laboratory Medicine,2016,31(04):38-40.[doi:10.3969/j.issn.16717-414.2016.04.009]
点击复制

Titin抗体检测在重症肌无力并发胸腺瘤诊断中的价值()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第31卷
期数:
2016年04期
页码:
38-40
栏目:
论著
出版日期:
2016-08-10

文章信息/Info

Title:
Clinical Significance of Titin Antibody Detection in the Diagnosis of Myasthenia Gravis Combined Thymoma
文章编号:
1671-7414(2016)04-038-03
作者:
梁 芸; 万玲玲; 李玉雪; 王之瑜; 杨红霞; 郑 梅
石家庄市第一人民医院,石家庄 050051
Author(s):
LIANG Yun; WAN Ling-ling; LI Yu-xue; WANG Zhi-yu; YANG Hong-xia; ZHENG Mei
the First People's Hospital of Shijiazhuang,Shijiazhuang 050051,China
关键词:
重症肌无力;  连结素抗体;  胸腺瘤
分类号:
R746.1; R392.11
DOI:
10.3969/j.issn.16717-414.2016.04.009
文献标志码:
A
摘要:
目的 探讨连结素(Titin)抗体检测在重症肌无力(MG)并发胸腺瘤患者诊断中的价值。方法 选取2013年1月～2014年11月石家庄市第一人民医院收治的MG患者56例,其中并发胸腺瘤患者(MGT)36例,不伴胸腺瘤MG组(NTMG)56例,其他疾病患者(OND)30例,健康对照组(HC)50例。采用酶联免疫吸附试验(ELISA)对重症肌无力患者、其他疾病患者和健康对照组进行Titin抗体检测并进行比较。结果 Titin抗体在MGT组、NTMG组、OND组和HC组的阳性率分别为88.9%,10.7%,6.7%和2.0%。MGT组的Titin抗体阳性率较NTMG组、OND组和HC组均显著升高(χ2=52.1,41.1,63.2,均P=0.000),而NTMG组、OND组和HC组间比较差异无统计学意义(χ2=0.051,P=0.821,χ2=1.993,P=0.158)。Titin抗体诊断MG并发胸腺瘤患者的敏感度为88.9%,特异度为89.3%。按照Osserman临床分型,Ⅰ,Ⅱ,Ⅲ及Ⅳ型MG患者的Titin抗体阳性率分别为11.8%,47.6%,83.3%和100%。Titin抗体阳性率与MG患者临床分型具有统计学意义(χ2=9.09,P=0.028)。结论 Titin抗体是MG并发胸腺瘤特异和敏感的血清学诊断指标。Titin抗体阳性率越高,可提示重症肌无力患者病情越严重。
Abstract:
Objective to evaluate the role of Titin antibody detection in the diagnosis of myasthenia gravis(MG)combined thymoma.Methods Selected hospital treated 92 cases of patients with MG from January 2013 and November 2014 in the First People's Hospital of Shijiazhuang,including 36 patients with thymoma(MGT),56 patients not with thymoma MG group(NTMG),30 patients with other diseases and 50 cases of Healthy control group.Titin antibody in patients with MG and Healthycontrol group were detected by Enzyme-linked immunosorbent assay(ELISA).Results Titin antibodies in the MG group combined thymoma(MGT), not with thymoma MG group(NTMG)and other diseases control(OND)and healthy controls(HC)positive rate was 88.9%,10.7%,6.7% and 88.9% respectively.MGT Titin antibody positive rate were significantly higher than NTMG group,OND group and HC group(χ2=52.1,41.1,63.2,all P=0.000),while NTMG,OND group and HC groups had no statistical significance(χ2=0.051 P=0.821; χ2=1.993 P=0.158),the positive rate of Titin antibody was significantly positive correlation with thymoma lesions(χ2=9.09 P=0.028).The sensitivity of Titin antibodies in the diagnosis of MG with thymoma was 88.9%,specificity of 89.3%.According to the Osserman clinical classification,positive rate of Titin antibodies MG patients with Type Ⅰ,Ⅱ,Ⅲ and Ⅳ were 11.8%,47.6%,11.8%,100% respectively.Positive rate of Titin antibody were statistical correlation with clinical classification of MG patients(χ2=9.09,P=9.09).Conclusion Titin antibody is MG combined thymoma specific and sensitive serological indicator.High positive rate of Titin antibody can prompt severity diseas.

参考文献/References:

[1] Szczudlik P,Szyluk B,Lipowska M,et al.Antititin antibody in early and late-onset myasthenia gravis[J].Acta Neurol Scand,2014,130(4):229-233.
[2] Tsai Y,Lin Y,Chen C,et al.Thymoma associated with myasthenia gravis and sjogren syndrome[J].West Indian Med J,2013,62(3):264-265.
[3] 吴君霞.重症肌无力相关自身抗体的研究进展[J].医学综述,2013,19(19):3491-3493. Wu JX.Research progress in myasthenia gravis related autoantibodies[J].Medical Recapitulate,2013,19(19):3491-3493.
[4] He ZF,Lu W,Qiao J,et al.Thymic expression of the main immunogenic region of titin in thymomatoas myasthenia gravis[J].J Int Med Res,2010,38(4):1324-1332.
[5] Ylimaz V,Oflazer P,Aysal F,et al.Differential cytokine changes in myasthenia gravis patients with antibodies against AChR and MusK[J].Plos One,2015,10(4):e123546.
[6] Sun C, Meng F, Li Y,et al.Antigen-specific immunoadosorption of anti-acetylcholine receptor antibodies from sera of patients with myasthenia gravis[J].Artif Cells Blood Substit Immobil Biotechnol,2010,38(1):99-102.
[7] Pasnoor M,Wolfe GI,Nations S,et al.Clinical findings in MusK-antibody positive myasthenia gravis:a U.S.experience[J].Muscle Nerve,2010,41(3):370-374.
[8] Suzuki S,Utsugisawa K,Nagane Y,et al.Three types of striational antibodies in myasthenia gravis[J].Autoimmune Dis,2011(2011):740583.
[9] Romi F.Thymoma in myasthenia gravis:from diagnosis to treatment[J].Autoimmune Disease,2011(2011):474512.

相似文献/References:

[1]刘挺挺,李 虎,马 炜,等.重症肌无力患者外周血中性粒细胞/淋巴细胞比值和血小板/淋巴细胞比值的临床意义[J].现代检验医学杂志,2016,31(01):65.[doi:10.3969/j.issn.1671-7414.2016.01.018]
　LIU Ting-ting,LI Hu,MA Wei,et al.Clinical Significance of Neutrophils/Lymphocyte and Platelet/Lymphocyte Ratio of Peripheral Blood in Patients with Myasthenia Gravis[J].Journal of Modern Laboratory Medicine,2016,31(04):65.[doi:10.3969/j.issn.1671-7414.2016.01.018]
[2]段海燕,张　华,杨　波.重症肌无力患儿血清 YKL-40水平变化及临床意义[J].现代检验医学杂志,2022,37(01):186.[doi:10.3969/j.issn.1671-7414.2022.01.038]
　DUAN Hai-yan,ZHANG Hua,YANG Bo.Changes of Serum YKL-40 Level in Children with Myasthenia Gravis and Its Clinical Significance[J].Journal of Modern Laboratory Medicine,2022,37(04):186.[doi:10.3969/j.issn.1671-7414.2022.01.038]

备注/Memo

备注/Memo:
基金项目:河北省卫生厅医学科研重点课题(ZD20140068)。
作者简介:梁 芸(1977-),女,主治医师,Tel:13731124820,E-mail:1804361078@qq.com。
更新日期/Last Update: 2016-08-10